Apellis pharmaceuticals, inc. (APLS)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Operating expenses:
Research and development

220,968

105,285

40,303

22,978

13,730

Cost of acquired in-process research and development

-

-

-

-

26,486

General and administrative

67,046

22,639

10,463

4,303

6,356

Operating loss

-288,015

-127,924

-50,767

-27,282

-46,573

Loss on extinguishment of debt

-1,501

-

-

-

-

Loss from remeasurement of development derivative liability

-14,839

-

-

-

-

Interest income

5,108

2,960

277

135

-

Interest expense

5,284

2,512

374

-

-

Interest income (expense), net

-

-

-

-

50

Other income/(expense), net

-175

-25

-142

22

6

Net loss

-304,706

-127,502

-51,006

-27,124

-46,515

Other comprehensive gain:
Foreign currency gain/ (loss)

-30

-122

-

-

-

Total other comprehensive gain/ (loss)

-30

-122

-

-

-

Comprehensive loss, net of tax

-304,737

-127,625

-51,006

-27,124

-

Net loss per common share, basic and diluted

-4.90

-2.34

-3.68

-3.22

-8.03

Weighted-average number of common shares used in net loss per common share, basic and diluted

62,228

54,396

13,870

8,428

5,795